Nobel Prize-winning physicist J. Michael Kosterlitz met with Chinese academic researchers and state-owned corporate executives in southeastern China to discuss how fundamental discoveries in condensed matter physics can advance quantum computing and new materials, an appearance that underscores the delicate balance facing U.S.-based scientists engaging with China's strategic technology sector.
Kosterlitz, a physics professor at Brown University and a member of the U.S. National Academy of Sciences who shared the 2016 Nobel Prize in Physics for his theoretical work on topological phase transitions, attended a quantum technology roundtable hosted by state-owned conglomerate Xiamen Xiangyu Group on Nov. 13.
The gathering convened researchers from Chinese universities and state-affiliated laboratories alongside corporate leaders to examine frontier physics, supply chain opportunities and cross-sector collaboration. Participants included Sichuan University professor Ao Ping, Shenzhen International Quantum Academy researcher Chen Yongcong, Tan Kah Kee Innovation Laboratory associate researcher Wu Shaoping, and Xiamen University School of Physical Science and Technology Dean Chen Zhanghai alongside associate professor Hu Quanxin. Xiangyu Group Chairman Deng Qidong and Vice President Wang Jianli represented the host enterprise.
Kosterlitz's participation comes amid heightened geopolitical friction and regulatory oversight in Washington regarding scientific exchanges with China in sensitive fields. U.S. national security officials classify quantum information science and advanced materials as critical dual-use technologies with major military implications, including applications in cryptography, code-breaking, secure communications and precision sensing.
For American and U.S.-based researchers, sharing technical insights in China carries strict legal and compliance boundaries. Under U.S. Export Administration Regulations, transferring non-public technical data, engineering know-how or proprietary methodologies to foreign nationals can constitute a regulated "deemed export," even when communicated verbally during academic roundtables or corporate consultations. While basic, fundamental research intended for open academic publication is generally exempt from federal export licensing, U.S. universities and federal funding agencies enforce rigorous disclosure and conflict-of-interest rules to prevent unauthorized technology transfer or participation in foreign state-backed talent programs.
Washington has also tightened trade restrictions on China's quantum sector, adding several Chinese quantum laboratories and technology enterprises to U.S. Commerce Department export blacklists. U.S. officials have pointed to Beijing's military-civil fusion strategy, which seeks to link civilian universities and state-owned conglomerates directly with defense modernization, warning that even high-level theoretical exchanges can carry compliance and reputational risks when hosted by state-linked entities aiming to accelerate applied engineering.
During the Xiamen dialogue, Kosterlitz focused on basic scientific principles, drawing upon his landmark discoveries in topological phases of matter to share insights on the laws governing fundamental research and the long-term trajectory of emerging technologies. Participating Chinese scholars and institute experts focused on the practical engineering hurdles of converting fragile quantum phenomena into stable hardware and how industrializing new materials can support quantum engineering.
The roundtable aligns with broader Chinese government initiatives to commercialize frontier science. Beijing has designated quantum technology as a priority future industry, and Xiamen municipal authorities have incorporated quantum development into the city's 15th Five-Year Plan, calling for expanded real-world testing scenarios, engineering verification and technology transfer.
Deng Qidong said Xiangyu Group, whose operations span supply chain management, modern logistics, advanced manufacturing, energy and new materials, aims to connect closely with international scientific talent and domestic universities so industrial demand can guide technical validation while patient capital sustains long-term innovation. Company officials added that the conglomerate will continue building mechanisms to link basic science directly to engineering verification and commercial production.


